Fracture risk reduction with denosumab in chronic kidney disease stage 3-5 - NI

Institute of Post Graduate Medical Education and Research0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年11月13日

试验速览

暂无简介。

•1.All the CKD patients in stage 3 to 5 visiting nephrology OPD of our institute or admitted in the department of Nephrology.
•2.Age older than 18 years.
•3.DEXA scan T score less than -2.5 (suggestive of osteoporosis) and/or FRAX score of >20% of major osteoporotic fracture and >3% for hip fracture.

•1.Patients with ongoing dialysis.
•2. Patients after total parathyroidectomy and evidence of severe hyper- or hypoparathyroidism (iPTH >800 or <10 ng/l)
•3.Patients treated with bisphosphonates, fluoride, calcitonin, or anabolic steroids within 1 year of enrolment.
•4. Hypocalcemia (total calcium <1.8 mmol/l or 7.2 mg/dl) or hypercalcemia(total calcium >2.7 mmol/l or 10.8 mg/dl)
•(patiennts will be included in the study after correction of hypo or hypercalcemia)
•5.Patients who are already received Denosummab, Teriparatide, SERM,Hormone replacement therapy, Romosuzumab.
•6. Active infections and/or malignancy.
•7.Ongoing pregnancy.

发起方

Institute of Post Graduate Medical Education and Research